🇺🇸 FDA
Patent

US 12084516

Anti-C5 antibody combinations and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12084516 (Anti-C5 antibody combinations and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K31/573